KPT-9274, a PAK4 and nicotinamide phosphoribosyltransferase (NAMPT) dual inhibitor, is the only one under phase I clinical trials (NCT02702492 and NCT04281420) for solid tumors and non-Hodgkin’s lymphoma [114,115,116]. This evidence concerns the gene NAMPT and non-Hodgkin lymphoma.